rs1801020 — F12 46C>T

5' UTR variant that reduces Factor XII translation efficiency, lowering plasma FXII levels and reducing contact activation coagulation

See your personal result for F12

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

Factor XII and the Contact Coagulation Paradox

Coagulation Factor XII (FXII), also called Hageman factor, is the initiating enzyme of the contact activation pathway11 contact activation pathway
The intrinsic coagulation pathway, triggered when blood contacts negatively charged surfaces such as glass, collagen, or bacterial polyphosphates of coagulation. When activated, FXII sets off a cascade that ultimately generates thrombin and produces a fibrin clot. FXII also activates the kallikrein-kinin system, generating bradykinin — a potent vasodilator implicated in inflammation and angioedema. The rs1801020 variant (known as 46C>T in papers, using the coding-strand notation of the minus-strand F12 gene) is the single most important common genetic determinant of circulating FXII levels, reducing protein production through a translational mechanism rather than a structural change.

The Mechanism

The F12 gene resides on chromosome 5q35.3 and is transcribed on the minus strand. The rs1801020 polymorphism sits in the 5' untranslated region (5'UTR)22 5' untranslated region (5'UTR)
The region of mRNA upstream of the protein-coding sequence; changes here affect translation efficiency without changing the protein sequence itself of F12, four nucleotides upstream of the normal start codon. The T allele (A on the plus strand) creates a new upstream ATG start codon that is read by ribosomes first, producing a short 2-amino-acid peptide that prevents the ribosome from reaching the authentic start site. This reduces translation of the full-length FXII protein. The effect is dose-dependent: CC carriers produce ~129% of average FXII; CT heterozygotes ~92%; TT homozygotes ~56%33 CC carriers produce ~129% of average FXII; CT heterozygotes ~92%; TT homozygotes ~56%
Calafell et al. Human Molecular Genetics 2010.

Bayesian quantitative trait nucleotide analysis44 Bayesian quantitative trait nucleotide analysis
A statistical method for identifying causal variants within a quantitative trait locus across 26 polymorphisms in the F12 locus confirmed that rs1801020 alone accounts for essentially all the heritable variation in plasma FXII levels, making it an unusually clean example of a single common variant with a large, well-defined biochemical effect.

The Evidence

The relationship between lower FXII levels and disease risk is paradoxical and evidence is mixed. Animal studies and human data converge on a surprising picture: low FXII appears protective against thrombosis, not harmful55 protective against thrombosis, not harmful
FXII-deficient mice are protected from pathological clotting without increased bleeding risk.

A meta-analysis of 16 candidate-gene studies (4,386 cases, 40,089 controls)66 meta-analysis of 16 candidate-gene studies (4,386 cases, 40,089 controls)
Johnson et al. Am J Epidemiology 2011 found only a borderline association with myocardial infarction for the dominant model (OR 1.13, 95% CI 1.00–1.27) and no significant association with venous thromboembolism, leading the authors to conclude the overall evidence is weak.

However, a Spanish case-control study of 250 venous thrombosis patients found that TT homozygotes had an adjusted OR of 4.82 (95% CI 1.5–15.6)77 adjusted OR of 4.82 (95% CI 1.5–15.6)
Tirado et al. Thrombosis and Haemostasis 2004 for VTE — a striking finding replicated in some but not all subsequent cohorts. The WOSCOPS study (441 CHD cases, 990 controls)88 WOSCOPS study (441 CHD cases, 990 controls)
Zito et al. Atherosclerosis 2002 found TT genotype to be an independent CHD risk factor (OR 1.48, 95% CI 1.01–2.17), particularly in pravastatin-treated subjects.

Separately, higher FXII protein levels — the opposite of what T allele carriers have — were associated with increased hemorrhagic stroke risk (HR 1.51 per SD, p<0.05)99 increased hemorrhagic stroke risk (HR 1.51 per SD, p<0.05)
Johansson et al. Cerebrovascular Diseases Extra 2017 in a northern Swedish prospective cohort, with no ischemic stroke association. This suggests FXII's role is complex: high levels may predispose to hemorrhagic vascular events while the effect of low levels on arterial thrombosis remains uncertain.

The Cardiovascular Health Study (n=5,411)1010 Cardiovascular Health Study (n=5,411)
Olson et al. J Thrombosis and Haemostasis 2015 confirmed that the T allele strongly lowers peak thrombin generation (β=−34.2 nM, p=3.3×10⁻²²) but found no association between rs1801020 genotype and incident ischemic stroke in a multi-cohort meta-analysis.

Practical Actions

For TT homozygotes (AA on the plus strand), FXII levels are approximately half of normal, substantially reducing contact pathway coagulation. While this does not cause clinical bleeding — Factor XII deficiency does not cause bleeding disorders even in severely deficient individuals1111 Factor XII deficiency does not cause bleeding disorders even in severely deficient individuals
unlike Factor VIII or IX deficiency — the cardiovascular implications warrant proactive monitoring. Some studies suggest elevated cardiovascular risk despite the anticoagulant effect, possibly mediated through reduced thrombolytic activity or kallikrein-kinin pathway dysregulation.

Heterozygotes (AG) have modestly reduced FXII (~92% of average) and a generally unremarkable risk profile, but may benefit from standard cardiovascular risk monitoring as part of routine care.

Interactions

The F12 gene interacts with prekallikrein (KLKB1, rs3733402) — both encode contact activation pathway enzymes that reciprocally activate each other. Carriers of reduced-function variants in both genes may experience synergistically lower contact pathway activity. The bradykinin arm of FXII activation also intersects with the renin-angiotensin system: rs1801020 and KLKB1 variants have been associated with reduced active renin formation. Compound carriers of rs1801020 TT and the KLKB1 rs3733402 low-activity genotype may warrant a combined evaluation of cardiovascular risk biomarkers.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Factor XII Normal

Normal Factor XII levels — full contact coagulation pathway activity

GG homozygotes at rs1801020 carry the ancestral F12 5'UTR sequence without the upstream ATG that reduces translation. This preserves efficient ribosomal access to the authentic start codon, resulting in full-length FXII production. Your FXII levels are expected to be in the upper range of the population distribution. Epidemiological data do not suggest increased cardiovascular risk from normal-high FXII, though one prospective study observed higher FXII levels associated with hemorrhagic stroke risk — an association not replicated for ischemic events.

AG Reduced Factor XII Intermediate

One copy of the reducing allele — moderately lower Factor XII levels

Heterozygous carriers have an intermediate FXII phenotype: one chromosomal copy produces full-length FXII normally, while the other carries the upstream ATG that competes with the authentic start codon. This single copy reduces overall FXII output modestly. The moderate reduction (from ~129% in GG to ~92% in AG) is unlikely to produce clinical bleeding and is below the threshold associated with symptomatic Factor XII deficiency (typically <50% of normal activity). Large meta-analyses have not found significant cardiovascular risk at the heterozygous level. Cardiovascular Health Study data confirm reduced thrombin generation in T-allele carriers, but without a detectable increase in ischemic stroke risk.

AA Low Factor XII Reduced

Two copies of the reducing allele — FXII levels approximately half of normal

AA homozygotes carry two copies of the upstream ATG-creating T allele. Both F12 gene copies produce the competing short peptide, leaving substantially less ribosomal capacity for authentic FXII translation. Plasma FXII activity will typically fall around 50–60% of the population mean — below the lower end of normal reference ranges at some clinical laboratories, though not in a range associated with haemostatic failure.

The paradox of this genotype: while FXII is pro-coagulant (high FXII promotes clotting), the epidemiological data on very low FXII and cardiovascular risk are inconsistent. The Spanish Thrombosis study (n=250) found an OR of 4.82 for VTE in TT homozygotes; the WOSCOPS study found OR 1.48 for CHD. However, the large HuGE meta-analysis (n>40,000) found only borderline MI association and no VTE signal. Modern large-scale genomics data suggests F12 haploinsufficiency may be protective against VTE rather than harmful.

The most clinically actionable implication: your aPTT will typically be prolonged (FXII deficiency is the commonest cause of unexplained aPTT prolongation in otherwise healthy people), and surgeons and anesthesiologists should be informed before procedures that use activated coagulation time (ACT) monitoring, as results will be misleading.